Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib

Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high impact on patients’ daily activities that remains difficult to treat. The knowledge acquired over the last decade on AD pathophysiology and disease burden led to the development of new targeted therapeutic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miguel Nogueira, Tiago Torres
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2021
Materias:	atopic dermatitis treatment janus kinase inhibitors abrocitinib baricitinib upadacitinib Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/f2263195ebd44087a6390424e7c41784
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2263195ebd44087a6390424e7c41784
record_format	dspace
spelling	oai:doaj.org-article:f2263195ebd44087a6390424e7c417842021-11-15T15:16:19ZJanus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib10.5826/dpc.1104a1452160-9381https://doaj.org/article/f2263195ebd44087a6390424e7c417842021-10-01T00:00:00Zhttps://dpcj.org/index.php/dpc/article/view/2121https://doaj.org/toc/2160-9381 Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high impact on patients’ daily activities that remains difficult to treat. The knowledge acquired over the last decade on AD pathophysiology and disease burden led to the development of new targeted therapeutic options that enable clinicians to better manage AD patients. The JAK/STAT signaling pathway modulates several immune pathways (T helper (Th)1, Th2, Th17, and Th22 cells) that have been found to be involved in AD pathogenesis. For this reason, JAK inhibitors emerged as a possible therapy for AD. Baricitinib, upadacitinib, and abrocitinib are the three oral JAK inhibitors already approved or in advanced clinical development for this purpose. The results showed that this drug class is highly effective achieving symptomatic relief (itch control) in the short term, as well as improving disease severity in the short and medium term. However, their efficacy should be balanced with possible side effects, that have been reported in clinical trials. More data on the long-term efficacy and safety, as well as from head-to-head comparisons and from real-world setting will be crucial to position oral JAK inhibitors in the AD therapeutic armamentarium. Miguel NogueiraTiago TorresMattioli1885articleatopic dermatitistreatmentjanus kinase inhibitorsabrocitinibbaricitinibupadacitinibDermatologyRL1-803ENDermatology Practical & Conceptual (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atopic dermatitis treatment janus kinase inhibitors abrocitinib baricitinib upadacitinib Dermatology RL1-803
spellingShingle	atopic dermatitis treatment janus kinase inhibitors abrocitinib baricitinib upadacitinib Dermatology RL1-803 Miguel Nogueira Tiago Torres Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
description	Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high impact on patients’ daily activities that remains difficult to treat. The knowledge acquired over the last decade on AD pathophysiology and disease burden led to the development of new targeted therapeutic options that enable clinicians to better manage AD patients. The JAK/STAT signaling pathway modulates several immune pathways (T helper (Th)1, Th2, Th17, and Th22 cells) that have been found to be involved in AD pathogenesis. For this reason, JAK inhibitors emerged as a possible therapy for AD. Baricitinib, upadacitinib, and abrocitinib are the three oral JAK inhibitors already approved or in advanced clinical development for this purpose. The results showed that this drug class is highly effective achieving symptomatic relief (itch control) in the short term, as well as improving disease severity in the short and medium term. However, their efficacy should be balanced with possible side effects, that have been reported in clinical trials. More data on the long-term efficacy and safety, as well as from head-to-head comparisons and from real-world setting will be crucial to position oral JAK inhibitors in the AD therapeutic armamentarium.
format	article
author	Miguel Nogueira Tiago Torres
author_facet	Miguel Nogueira Tiago Torres
author_sort	Miguel Nogueira
title	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
title_short	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
title_full	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
title_fullStr	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
title_full_unstemmed	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
title_sort	janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib
publisher	Mattioli1885
publishDate	2021
url	https://doaj.org/article/f2263195ebd44087a6390424e7c41784
work_keys_str_mv	AT miguelnogueira januskinaseinhibitorsforthetreatmentofatopicdermatitisfocusonabrocitinibbaricitinibandupadacitinib AT tiagotorres januskinaseinhibitorsforthetreatmentofatopicdermatitisfocusonabrocitinibbaricitinibandupadacitinib
_version_	1718428227859382272

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib

Ejemplares similares